These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 22609245)

  • 21. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
    Chapman MJ
    Pharmacol Ther; 2006 Sep; 111(3):893-908. PubMed ID: 16574234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipoprotein(a) particle concentration and lipoprotein(a) cholesterol assays yield discordant classification of patients into four physiologically discrete groups.
    Konerman M; Kulkarni K; Toth PP; Jones SR
    J Clin Lipidol; 2012; 6(4):368-73. PubMed ID: 22836074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel targets that affect high-density lipoprotein metabolism: the next frontier.
    Davidson MH; Rosenson RS
    Am J Cardiol; 2009 Nov; 104(10 Suppl):52E-7E. PubMed ID: 19895945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
    Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advancing therapy for hypercholesterolemia.
    Toutouzas K; Drakopoulou M; Skoumas I; Stefanadis C
    Expert Opin Pharmacother; 2010 Jul; 11(10):1659-72. PubMed ID: 20509773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of HDL in those with diabetes.
    Santos-Gallego CG; Rosenson RS
    Curr Cardiol Rep; 2014 Sep; 16(9):512. PubMed ID: 25199216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trial clouds use of niacin with a statin.
    Harv Heart Lett; 2011 Aug; 21(12):2. PubMed ID: 21991606
    [No Abstract]   [Full Text] [Related]  

  • 28. LDL and HDL subfractions, dysfunctional HDL: treatment options.
    Garcia-Rios A; Nikolic D; Perez-Martinez P; Lopez-Miranda J; Rizzo M; Hoogeveen RC
    Curr Pharm Des; 2014; 20(40):6249-55. PubMed ID: 24953394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of hypertriglyceridemia with fibric acid derivatives: impact on lipid subfractions and translation into a reduction in cardiovascular events.
    McCullough PA; Ahmed AB; Zughaib MT; Glanz ED; Di Loreto MJ
    Rev Cardiovasc Med; 2011; 12(4):173-85. PubMed ID: 22249508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospects for the development of novel anti-hyperlipidemic drugs.
    Derosa G; Salvadeo S; Cicero AF
    Curr Opin Investig Drugs; 2006 Sep; 7(9):826-33. PubMed ID: 17002261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials.
    Taylor AJ
    Am J Cardiol; 2008 Apr; 101(8A):36B-43B. PubMed ID: 18375240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The treatment of dyslipidemia--what's left in the pipeline?
    Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M
    ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The potential role of HDL- and LDL-cholesterol modulation in atheromatous plaque development.
    Chapman MJ
    Curr Med Res Opin; 2005; 21 Suppl 6():S17-22. PubMed ID: 16138937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patients with low levels of high-density lipoprotein cholesterol: to treat or not to treat?
    Tavintharan S; Lim SC; Sum CF
    Singapore Med J; 2005 Oct; 46(10):519-28. PubMed ID: 16172771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease.
    Shah PK
    Eur Heart J; 2007 Jan; 28(1):5-12. PubMed ID: 17121756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HDL as a target in the treatment of atherosclerotic cardiovascular disease.
    Linsel-Nitschke P; Tall AR
    Nat Rev Drug Discov; 2005 Mar; 4(3):193-205. PubMed ID: 15738977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-density lipoprotein metabolism: potential therapeutic targets.
    Davidson MH; Toth PP
    Am J Cardiol; 2007 Dec; 100(11 A):n32-40. PubMed ID: 18047851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-density lipoprotein: a fall from grace?
    van Leuven SI; Stroes ES; Kastelein JJ
    Ann Med; 2008; 40(8):584-93. PubMed ID: 18608128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-density lipoprotein therapeutics and cardiovascular prevention.
    Fazio S; Linton MF
    J Clin Lipidol; 2010; 4(5):411-9. PubMed ID: 21122685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.